Answers are grounded in this paper and cite their sources.
Oral corticosteroids are first-line therapy for allergic bronchopulmonary aspergillosis (ABPA), however, itraconazole has been recognized as an adjunctive treatment. This paper describes the prolonged use of itraconazole in an asthmatic patient with a diagnosis of ABPA. This case report features a patient who showed benefit with a longer duration of itraconazole therapy without demonstrating adverse events related to treatment over nearly eight years. Prolonged treatment with itraconazole may serve as a corticosteroid sparing option for ABPA patients.
No takes yet. Share an insight, caveat, or question.
Nguyen et al. (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: